172 completed, 20 terminated, 19 unknown, 12 withdrawn. 225 Phase 3, 25 Phase 2.
Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Favipiravir, Ribavirin, Dexamethasone - Lassa Fever | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | 1755 | 2025-05-02 | 2026-02-04 |
| The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Khyber Medical University Peshawar | 284 | 2024-12-17 | 2025-06-26 |
| Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19 | Phase 2 / Phase 3 | Unknown | The Scientific and Technological Research Council of Turkey | 100 | 2021-04-01 | 2021-04-02 |
| New Antiviral Drugs for Treatment of COVID-19 Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : - COVID, Drug Effect | Phase 3 | Unknown | Mansoura University | 100 | 2020-10-01 | 2020-09-03 |
| A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients TG-2349, DAG181, Ribavirin - Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic | Phase 3 | Completed | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 370 | 2019-06-13 | 2021-02-04 |
| Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity Ribavirin, Tenofovir - Hepatitis B, Chronic | Phase 3 | Unknown | Ottawa Hospital Research Institute | 24 | 2019-01-10 | 2021-09-14 |
| Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) Peginterferon alpha-2a + Ribavirin - Chronic Hepatitis | Phase 3 | Completed | Casa Sollievo della Sofferenza IRCCS | 1150 | 2018-12-01 | 2022-03-24 |
| Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. Ravidasvir, Danoprevir, Ritonavir - HCV | Phase 2 / Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 425 | 2017-07-01 | 2020-07-28 |
| Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet - Hepatitis C, HCV | Phase 3 | Completed | University of Florida | 177 | 2017-04-20 | 2020-02-26 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis SOF/VEL, RBV - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 102 | 2016-12-26 | 2019-02-26 |
| Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients Sofosbuvir Oral Product, Ribavirin - Pharmacological Action | Phase 2 / Phase 3 | Unknown | National Liver Institute, Egypt | 41 | 2016-12-01 | 2016-12-19 |
| Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin - Hepatitis C Virus Infection | Phase 3 | Completed | AbbVie | 33 | 2016-11-21 | 2022-05-04 |
| Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV daclatasvir, asunaprevir, Ribavirin - Hepatitis C | Phase 3 | Completed | Kaohsiung Medical University Chung-Ho Memorial Hospital | 70 | 2016-11-01 | 2019-01-09 |
| A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection Dactavira Plus, Sofosbuvir + Daclatasvir + Ribavirin, Dactavira - Hepatitis C | Phase 3 | Completed | Egyptian Liver Hospital | 72 | 2016-09-01 | 2017-12-27 |
| Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Sofosbuvir, Ledipasvir, Ribavirin - Hepatitis C, Cirrhosis | Phase 3 | Completed | Tehran University of Medical Sciences | 50 | 2016-09-01 | 2018-04-30 |
| Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. Grazoprevir 100 mg/day, Elbasvir 50 mg/d, Elbasvir 50 mg/day - Liver Transplantation, Hepatitis C | Phase 3 | Withdrawn | Fundacion Clinic per a la Recerca Biomédica | 2016-08-03 | 2025-06-22 | |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen SOF/VEL, RBV - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 117 | 2016-07-25 | 2018-11-14 |
| Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin - Hepatitis C, Acute | Phase 3 | Completed | Kirby Institute | 83 | 2016-06-01 | 2022-08-22 |
| Swiss HCVree Trial grazoprevir/elbasvir, ribavirin, Behavioural Intervention - Hepatitis C, HIV | Phase 3 | Completed | University of Zurich | 150 | 2016-06-01 | 2018-08-31 |
Showing 20 of 225. Sign in to see all of them.
Hepatitis C (123) · Hepatitis C, Chronic (122) · Fibrosis (12) · HIV Infections (10) · Hepatitis (8) · Liver Cirrhosis (8) · Infections (6) · Hepatitis, Chronic (4) · Hepatitis B (3) · Hepatitis B, Chronic (3) · Liver Diseases (3) · Acquired Immunodeficiency Syndrome (2) · Bronchiolitis Obliterans Syndrome (2) · COVID-19 (2) · Carcinoma, Hepatocellular (2)
Merck Sharp & Dohme LLC (30) · AbbVie (23) · Bristol-Myers Squibb (18) · Gilead Sciences (7) · Hoffmann-La Roche (6) · Tanabe Pharma Corporation (6) · AbbVie (prior sponsor, Abbott) (5) · Janssen R&D Ireland (5) · Bausch Health Americas, Inc. (4) · Boehringer Ingelheim (4) · Foundation for Liver Research (4) · Janssen Pharmaceutical K.K. (4) · Janssen-Cilag International NV (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · Vertex Pharmaceuticals Incorporated (4)
United States (58) · France (40) · Spain (39) · Germany (34) · Canada (32) · United Kingdom (32) · Italy (27) · Australia (25) · Puerto Rico (23) · Belgium (21) · Russia (21) · Japan (20) · Poland (20) · Austria (17) · Egypt (16)
Ralph T. Doyle (4) · Eric Cohen, MD (3) · Fumitaka Suzuki, MD (3) · Adriano Lazzarin, MD (2)
PMID 29377566, PMID 25445400, PMID 26947564, PMID 20189674, PMID 22239511, PMID 22626609, PMID 25196718, PMID 26321288, PMID 26743093, PMID 26936417, PMID 27920566, PMID 29404492, PMID 29461687, PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 16122679, PMID 16287208, PMID 16614742, PMID 16890601, PMID 17593061, PMID 17635375, PMID 17654600, PMID 17656331, PMID 17850410, PMID 17894303, PMID 17894323, PMID 18167062, PMID 18237873, PMID 18266997, PMID 18318441, PMID 18463735, PMID 18848939, PMID 19052125, PMID 19053983, PMID 19187068, PMID 19284286, PMID 19291787, PMID 19327119, PMID 19330875, PMID 19445938, PMID 19527724, PMID 19625712, PMID 19676128, PMID 19684573, PMID 19721480, PMID 19747918, PMID 19749757, PMID 19766643
2014 (8), 2015 (4), 2004 (2), 2005 (2), 2009 (2), 2008 (1), 2016 (1), U01DK060309 (1), U01DK060324 (1), U01DK060327 (1), U01DK060329 (1), U01DK060335 (1), U01DK060340 (1), U01DK060341 (1), U01DK060342 (1)